Article
Gastroenterology & Hepatology
Daniela Pugliese, Giuseppe Privitera, Federica Crispino, Nicolo Mezzina, Fabiana Castiglione, Gionata Fiorino, Lucrezia Laterza, Anna Viola, Lorenzo Bertani, Flavio Caprioli, Maria Cappello, Brigida Barberio, Chiara Ricci, Paola Balestrieri, Marco Daperno, Dario Pluchino, Fernando Rizzello, Maria Lia Scribano, Renato Sablich, Luca Pastorelli, Francesco Manguso, Angela Variola, Antonio Di Sario, Laurino Grossi, Alessandro Armuzzi
Summary: The study included 198 elderly (108 UC, 90 CD) and 396 matched nonelderly patients (205 UC, 191 CD). Nonelderly UC patients had a significantly higher persistence on vedolizumab compared to elderly patients. No significant difference in effectiveness was observed between elderly and nonelderly CD patients.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Gastroenterology & Hepatology
Nick Dai, Omar Haidar, Alan Askari, Jonathan P. Segal
Summary: This study aimed to understand the changing prevalence of colectomy in Ulcerative Colitis (UC) over time. The results showed that the overall colectomy rate has decreased over the past three decades. Biologics may have played a role in reducing the risk of colectomy, but the relative risk reduction is likely to be modest.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Surgery
Mohineesh Kumar, Rachel N. Harvey, Samuel K. Osei, Ayesha Fatima, Alexander Z. Menning, Begum Akay, Pavan Brahmamdam, Anthony Stallion, Nathan M. Novotny
Summary: This retrospective study analyzed the effectiveness of new biologics in treating pediatric ulcerative colitis. The results showed that these biologics played an important role in achieving remission, improving nutrition, and reducing the need for surgery. Surgery had a positive impact on nutrition and disease remission, suggesting that the addition of another biologic should consider the benefits of surgery.
Article
Gastroenterology & Hepatology
Kengo Kanayama, Jun Kato, Wataru Shiratori, Ariki Nagashima, Yuki Ohta, Takashi Taida, Keiko Saito, Chihiro Goto, Satsuki Takahashi, Ryosuke Horio, Akane Kurosugi, Tsubasa Ishikawa, Tatsuya Kaneko, Naoki Akizue, Kenichiro Okimoto, Tomoaki Matsumura, Naoya Kato
Summary: This study found that selecting subsequent treatment based on the response to initial anti-tumor necrosis factor (TNF)alpha antibody (ATA) is feasible in refractory ulcerative colitis (UC) patients. Non-ATA may be suitable as subsequent biologics for UC patients regardless of the efficacy of the first ATA.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Medicine, General & Internal
Alice Burgevin, Benedicte Caron, Alexa Sasson, Amandine Luc, Patrick Netter, Cedric Baumann, Ashwin N. Ananthakrishnan, Laurent Peyrin-Biroulet
Summary: The safety of vedolizumab and ustekinumab therapies in older patients with inflammatory bowel disease was compared. The study found that there was no difference in terms of safety between vedolizumab and ustekinumab in patients with Crohn's disease. The occurrence of adverse events per year of follow-up was also similar between vedolizumab and anti-TNF therapy for ulcerative colitis and Crohn's disease.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Ohad Atia, Sasha Harel, Natan Ledderman, Shira Greenfeld, Revital Kariv, Iris Dotan, Ran Balicer, Barbara Silverman, Eran Matz, Zohar Levi, Matti Waterman, Iris Fried, Jacob M. Rowe, Dan Turner
Summary: Pediatric onset inflammatory bowel disease (PIBD) patients have a higher risk of developing cancer compared to non-inflammatory bowel disease (IBD) children, but the absolute risk is very low, and no significant differences in risk were found among different treatment methods in our data.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Immunology
Yiyoung Kwon, Yoon Zi Kim, Yon Ho Choe, Mi Jin Kim
Summary: This study found that patients with high monocyte counts at the time of discontinuation were more likely to experience relapse after stopping biologics. The monocyte percentage can be used to predict the risk of relapse within 6 months after discontinuation.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Guillaume Le Cosquer, Lena Capirchio, Pauline Riviere, Marie Armelle Denis, Florian Poullenot, Christophe Remue, Frank Zerbib, Daniel Leonard, Bertrand Celerier, Alex Kartheuser, David Laharie, Olivier Dewit
Summary: This study aimed to determine the trend of colectomy in ulcerative colitis (UC) by comparing colectomy indications and outcomes between 2000 and 2010 and 2011-2020. The results showed that the proportion of surgery for refractory UC significantly decreased compared to other surgical indications while surgical outcomes improved despite larger exposure to biologics.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Medicine, General & Internal
Lorenzo Bertani, Brigida Barberio, Domenico Trico, Federico Zanzi, Daria Maniero, Linda Ceccarelli, Ilaria Marsilio, Francesca Coppini, Greta Lorenzon, Maria Gloria Mumolo, Fabiana Zingone, Francesco Costa, Edoardo Vincenzo Savarino
Summary: The study found that hospitalization for intravenous biologics treatment did not increase the risk of COVID-19 infection in patients with inflammatory bowel diseases during the COVID-19 outbreak. Additionally, there was a similar level of anxiety between patients receiving intravenous and subcutaneous drug treatments.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Neasa Mc Gettigan, Aman Shah Afridi, Grace Harkin, Caroline Lardner, Stephen Patchett, Danny Cheriyan, Gavin Harewood, Karen Boland, Aoibhlinn O'Toole
Summary: The study aimed to identify optimal management strategies for anti-drug antibodies (ADAs) in patients receiving infliximab (IFX) to prevent therapy discontinuation. Results showed that increasing IFX dosage and adjusting combination therapy can lower rates of discontinuation of IFX, with significant cut-off values for ADA trough levels and important clinical outcomes identified through ROC curve analysis.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2021)
Article
Gastroenterology & Hepatology
Tessa Straatmijer, Fiona D. M. van Schaik, Alexander G. L. Bodelier, Marijn Visschedijk, Annemarie C. de Vries, Cyriel Y. Ponsioen, Marieke Pierik, Ad A. van Bodegraven, Rachel L. West, Nanne K. H. de Boer, Nidhi Srivastava, Tessa E. H. Romkens, Jildou Hoekstra, Bas Oldenburg, Gerard Dijkstra, Janneke C. van der Woude, Mark Lowenberg, Zlatan Mujagic, Vince B. C. Biemans, Andrea E. Van der Meulen-de Jong, Marjolijn Duijvestein
Summary: The aim of this study was to evaluate the effectiveness and safety of 24 months of tofacitinib use in patients with ulcerative colitis in the Netherlands. The results showed that 31.8% of patients achieved corticosteroid-free clinical remission after 24 months of tofacitinib treatment. The main side effects were skin reactions and headaches.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Gastroenterology & Hepatology
Ole Haagen Nielsen, John Mark Gubatan, Carsten Bogh Juhl, Sarah Elizabeth Streett, Cynthia Maxwell
Summary: Adverse pregnancy outcomes among pregnant IBD women using biologics are comparable with that of the general population.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Jiaqi Yao, Ginenus Fekadu, Siew C. Ng, Joyce H. S. You
Summary: Based on the study, standard treatment plus FMT therapy appears to be more effective than standard therapy alone for patients with mild-to-moderate active UC. The cost-effectiveness of this treatment is highly dependent on the relative improvement in achieving remission with standard therapy plus FMT therapy and the number of FMT administrations per FMT course.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Koji Yokoyama, Yoko Yamamoto, Ryusuke Nambu, Shin-Ichiro Hagiwara, Daiki Abukawa, Tatsuki Mizuochi, Takahiro Kudo, Tomomitsu Sado, Naomi Iwata, Takashi Ishige, Itaru Iwama, Hideki Kumagai, Katsuhiro Arai, Toshiaki Shimizu
Summary: This study evaluated the safety and efficacy of Vedolizumab (VDZ) in pediatric ulcerative colitis (UC) patients in Japan. The results showed that VDZ was a safe and effective treatment option for children with UC. Hematocrit, albumin, and erythrocyte sedimentation rate (ESR) at VDZ initiation may predict VDZ effectiveness. This study is of great importance for treatment decisions in pediatric patients.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Medicine, General & Internal
Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Eirini Theodoraki, Ioannis E. Koutroubakis
Summary: Despite advancements in inflammatory bowel disease (IBD) management, anti-TNF agents continue to be the primary treatment for Crohn's disease and ulcerative colitis. However, optimizing treatment strategies is essential due to the progressive nature of the disease and potential loss of response. This overview examines the role of therapeutic drug monitoring (TDM), combining anti-TNF with immunomodulators, and the treat-to-target approach in enhancing the efficacy and outcomes of anti-TNF treatment.
JOURNAL OF CLINICAL MEDICINE
(2023)